Researcher index

Authors in the psilocybin and psilocin literature

Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.

Jurij Bon

68 indexed publications match this author name.

ORCID: 0000-0002-5303-2044
OpenAlex: https://openalex.org/A5079338766

Author watchlist

Create a confirmed email alert for new publications matching this author.

Topics

Safety 26 Depression 22 Receptor Pharmacology 22 Mechanism of Action 17 Pharmacology 16 Clinical Trial 15 Anxiety 14 Review Article 11 Addiction 10 Brain Imaging 9 Observational Study 9 Animal Study 8

Journals

bioRxiv 5 Journal of psychopharmacology (Oxford, England) 4 Psychopharmacology 4 ClinicalTrials.gov 3 Drug and Alcohol Dependence 3 Psychedelic medicine (New Rochelle, N.Y.) 2 The Australian and New Zealand journal of psychiatry 2 Molecular psychiatry 1

Publication history

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study.Psychedelic medicine (New Rochelle, N.Y.) · 2026-09-01 Psychedelics and women's mental health: the effects of female sex hormones on psychedelics' efficacy and tolerability.Molecular psychiatry · 2026-08-04 No evidence for deleterious effects of psilocybin and MDMA on working memory or related neurophysiological activity in a non-clinical population: An uncontrolled exploratory studyJournal of Psychopharmacology · 2026-07-23 Sex Differences in Acute Responses to Psychedelics: Evidence for Greater Subjective Intensity and Impairment in Female ParticipantsbioRxiv · 2026-07-13 Psychedelics stores, their regulation and public health: knowledge, perceptions, attitudes and opinions of Canadians.The International journal on drug policy · 2026-07-09 The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review.Journal of psychopharmacology (Oxford, England) · 2026-07-01 Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-22 The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.ClinicalTrials.gov · 2026-05-08 Pilot Results for Psilocybin-Assisted Psychotherapy for Cocaine Use Disorder-A Critical AppraisalJAMA Network Open · 2026-05-07 A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experienceFrontiers in Public Health · 2026-04-14 Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 StudyPsychedelic Medicine · 2026-01-18 Oregon's Psilocybin Services: A Summary and Public Health Commentary.Health behavior research · 2026-01-01 Exploring Determinants of Psilocybin Acceptance as an Alternative Modality for Major Depressive Disorder: A Pilot StudyJournal of Complementary and Alternative Medical Research · 2025-12-16 Salience, sensemaking, and setting in psilocybin microdosingRepository of the University of Ljubljana (University of Ljubljana) · 2025-11-18 Serotonin 5-HT Receptor Signaling Analysis Reveals Psychedelic Biased Agonism.ACS chemical neuroscience · 2025-10-01 Serotonin 5-HT2C Receptor SignalingAnalysis Reveals Psychedelic Biased AgonismFigshare · 2025-09-13 Psilocybin biosynthesis enhancement through gene source optimization.Metabolic engineering · 2025-09-01 620. IDENTIFICATION OF BLOOD BIOMARKERS OF PSILOCYBIN-ASSISTED THERAPY TREATMENT RESPONSE FOR GENERALISED ANXIETY DISORDERThe international journal of neuropsychopharmacology · 2025-08-01 Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms.Fundamental & clinical pharmacology · 2025-08-01 Understanding the Psychological Effects of Psilocybin and 3,4-Methylenedioxymethamphetamine in a Non-Clinical PopulationmedRxiv · 2025-05-29 Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humansScientific Reports · 2025-04-21 Selective outcome reporting and non-reporting in trials of psychedelic drugs for mental disordersEuropean Psychiatry · 2025-04-01 The safety of psilocybin-assisted psychotherapy: A systematic review.The Australian and New Zealand journal of psychiatry · 2025-02-01 Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications.Pharmaceuticals (Basel, Switzerland) · 2025-01-19 Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial.JAMA network open · 2024-12-02 Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy.Psychedelic medicine (New Rochelle, N.Y.) · 2024-12-01 Pharmacological and behavioural effects of tryptamines present in psilocybin-containing mushrooms.British journal of pharmacology · 2024-10-01 Salience, sensemaking, and setting in psilocybin microdosing: Methodological lessons and preliminary findings of a mixed method qualitative studyPhilosophical Psychology · 2024-09-26 A virtual clinical trial of psychedelics to treat patients with disorders of consciousnessbioRxiv · 2024-08-19 Ketamine-Induced Unresponsiveness Shows a Harmonic Shift from Global to Localised Functional OrganisationbioRxiv · 2024-06-25 Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2024-04-01 Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study.European journal of pain (London, England) · 2024-01-01 The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.Current neuropharmacology · 2024-01-01 Revisiting psychiatry's relationship with spirituality.Frontiers in psychiatry · 2024-01-01 Evaluation of TrpM and PsiD substrate promiscuity reveals new biocatalytic capabilities.Biotechnology progress · 2024-01-01 Beyond the 5-HT Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action.The Journal of neuroscience: the official journal of the Society for Neuroscience · 2023-11-08 Psilocybin-assisted psychotherapy for the treatment of PTSD in UK armed forces veterans: A feasibility study protocolEuropean Journal of Trauma & Dissociation · 2023-10-25 Pharmacological and behavioral effects of tryptamines present in psilocybin-containing mushroomsbioRxiv · 2023-10-23 Substance use, harm reduction attitudes and behaviors among attendees of nature rave parties in Israel.Harm reduction journal · 2023-08-09 "Biosynthesis of psilocybin and its nonnatural derivatives by a promiscuous psilocybin synthesis pathway in Escherichia coli".Biotechnology and bioengineering · 2023-08-01 Psilocybin's effects on cognition and creativity: A scoping review.Journal of psychopharmacology (Oxford, England) · 2023-07-01 In vivo mapping of pharmacologically induced functional reorganization onto the human brain's neurotransmitter landscape.Science advances · 2023-06-16 The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionClinicalTrials.gov · 2023-04-24 Effect of psilocybin on decision-making and motivation in the healthy rat.Behavioural brain research · 2023-02-25 Considerations in assessing the abuse potential of psychedelics during drug development.Neuropharmacology · 2023-02-15 The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.International journal of molecular sciences · 2023-01-10 In Search of: A Federal Safe Harbor for State Legalization of PsilocybinLewis & Clark Law Review · 2023-01-01 Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome.Psychopharmacology · 2023-01-01 Mapping Pharmacologically-induced Functional Reorganisation onto the Brain’s Neurotransmitter LandscapebioRxiv · 2022-07-13 Classic and non-classic psychedelics for substance use disorder: A review of their historic, past and current researchAddiction Neuroscience · 2022-06-22 Development of an -based norbaeocystin production platform and evaluation of behavioral effects in rats.Metabolic engineering communications · 2022-06-01 Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives.Frontiers in psychology · 2022-01-01 Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.The Australian and New Zealand journal of psychiatry · 2021-12-01 Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?Bioengineered · 2021-12-01 Discriminative Stimulus Effects of Substituted Tryptamines in Rats.ACS pharmacology & translational science · 2021-04-09 Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches.Journal of psychopharmacology (Oxford, England) · 2021-04-01 Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [C]MDL100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation.Frontiers in neuroergonomics · 2021-01-01 Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan.Psychopharmacology · 2020-08-01 New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological IssuesCurrent Addiction Reports · 2019-04-22 Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.Psychopharmacology · 2018-10-01 Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.Psychopharmacology · 2018-02-01 Comparison of anomalous experiences after ingesting psilocybin mushrooms in research and non-research settingsDrug and Alcohol Dependence · 2017-01-21 Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.Journal of psychopharmacology (Oxford, England) · 2016-12-01 Comparative phenomenology of psilocybin experiences in research and non-research settingsDrug and Alcohol Dependence · 2015-10-31 Survey study of challenging experiences after ingesting psilocybin mushrooms: Demographics and phenomenologyDrug and Alcohol Dependence · 2014-12-16 Chemical Constituents of Gymnopilus spectabilis and Their Antioxidant Activity.Mycobiology · 2008-03-01 Psychoactivity of normacromerine in animals.Life sciences · 1978-08-30 The effect of psilocybin upon the systemic, pulmonary, and coronary circulation of the intact dog.Archives internationales de pharmacodynamie et de therapie · 1962-05-01

Author directory